B-Cell Maturation Antigen | Research | BMS Science | HCP Site
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
VisualAbstract: Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma | 2 Minute Medicine
Different constructs of CARs targeting BCMA. BCMA is an antigen that... | Download Scientific Diagram
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma | PNAS
Anti-BCMA CAR-T Preclinical In Vivo Assay - Creative Biolabs
Improving Multiple Myeloma CAR T-Cell Therapy - NCI
Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies - ScienceDirect
IJMS | Free Full-Text | Comparison of FACS and PCR for Detection of BCMA-CAR -T Cells
Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? | Leukemia
Accelerating clinical-scale production of BCMA CAR T cells with defined maturation stages: Molecular Therapy - Methods & Clinical Development
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia - Li - 2021 - Clinical and Translational Medicine - Wiley Online Library
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells: Molecular Therapy - Methods & Clinical Development
Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma | Journal for ImmunoTherapy of Cancer
FDA Approves Carvykti CAR T-Cell Therapy for Multiple Myeloma - NCI
Frontiers | Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia - ScienceDirect
Effective anti-BCMA retreatment in multiple myeloma - ScienceDirect
Frontiers | Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector: Molecular Therapy
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma | bioRxiv
